Piper Jaffray has published a research report on Medical Diagnostics, writing "Our positive 4Q10 STD channel checks suggest a combination of a deductible flush and easier H1N1 comps in December. Not surprisingly, there is concern about the effect of resetting deductibles on 1Q11 trends. We believe an increase in flu trends plus an incremental effect from the early health care reform changes could offset any negative impact and position the group for a sustainable improvement in visit trends ahead of any employment-based recovery. Accordingly, we continue to view stocks such as BDX, DGX, GPRO, HOLX, LH and QGEN as early beneficiaries of this trend."
Companies related to this report include:
Becton, Dickinson and Co. BDX $83.13
Quest Diagnostics, Inc. DGX $55.17
Gen-Probe, Inc. GPRO $59.68
Hologic, Inc. HOLX $18.88
Laboratory Corp. Of America LH $91.81
Qiagen NV QGEN $19.44
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst Ratingsbecton dickinson & cogen-probeHealth CareHealth Care EquipmentHealth Care ServiceshologicLaboratory Corporation of AmericaLife Sciences Tools & ServicesPiper JaffrayQiagenquest diagnostics
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in